Faculty Opinions recommendation of Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.

作者
Helmy M. Siragy
出处
期刊:
标识
DOI:10.3410/f.738717029.793581582
摘要

BACKGROUND: It is thought that a reduction in the frequency of basal insulin injections might facilitate treatment acceptance and adherence among patients with type 2 diabetes. Insulin icodec is a basal insulin analogue designed for once-weekly administration that is in development for the treatment of diabetes.METHODS: We conducted a 26-week, randomized, double-blind, double-dummy, phase 2 trial to investigate the efficacy and safety of once-weekly insulin icodec as compared with once-daily insulin glargine U100 in patients who had not previously received long-term insulin treatment and whose type 2 diabetes was inadequately controlled (glycated hemoglobin level, 7.0 to 9.5%) while taking metformin with or without a dipeptidyl peptidase 4 inhibitor. The primary end point was the change in glycated hemoglobin level from baseline to week 26. Safety end points, including episodes of hypoglycemia and insulin-related adverse events, were also evaluated.RESULTS: A total of 247 participants were randomly assigned (1:1) to receive icodec or glargine. Baseline characteristics were similar in the two groups; the mean baseline glycated hemoglobin level was 8.09% in the icodec group and 7.96% in the glargine group. The estimated mean change from baseline in the glycated hemoglobin level was -1.33 percentage points in the icodec group and -1.15 percentage points in the glargine group, to estimated means of 6.69% and 6.87%, respectively, at week 26; the estimated between-group difference in the change from baseline was -0.18 percentage points (95% CI, -0.38 to 0.02, P = 0.08). The observed rates of hypoglycemia with severity of level 2 (blood glucose level, < 54 mg per deciliter) or level 3 (severe cognitive impairment) were low (icodec group, 0.53 events per patient-year; glargine group, 0.46 events per patient-year; estimated rate ratio, 1.09; 95% CI, 0.45 to 2.65). There was no between-group difference in insulin-related key adverse events, and rates of hypersensitivity and injection-site reactions were low. Most adverse events were mild, and no serious events were deemed to be related to the trial medications.CONCLUSIONS: Once-weekly treatment with insulin icodec had glucose-lowering efficacy and a safety profile similar to those of once-daily insulin glargine U100 in patients with type 2 diabetes. (Funded by Novo Nordisk; NN1436-4383 ClinicalTrials.gov number, NCT03751657.).Copyright © 2020 Massachusetts Medical Society. PMID: 32960514

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
shenmolianzzz发布了新的文献求助10
刚刚
1秒前
1秒前
辛勤的幻莲完成签到,获得积分10
1秒前
2秒前
cdy完成签到,获得积分10
2秒前
北柠发布了新的文献求助10
4秒前
souven完成签到,获得积分10
4秒前
4秒前
4秒前
星空发布了新的文献求助10
5秒前
5秒前
好好学习可以吗完成签到,获得积分10
5秒前
Auntiepress完成签到 ,获得积分10
6秒前
XiaoMu完成签到,获得积分20
6秒前
谨慎的绿真完成签到 ,获得积分10
6秒前
6秒前
李伟完成签到,获得积分10
6秒前
Visiony完成签到,获得积分10
7秒前
蔺天宇完成签到,获得积分0
7秒前
石中酒完成签到 ,获得积分10
7秒前
今天只做一件事完成签到,获得积分0
8秒前
8秒前
遇见多欢喜完成签到,获得积分10
9秒前
贪玩的秋柔完成签到,获得积分0
9秒前
9秒前
zyyyy发布了新的文献求助10
9秒前
兴奋飞荷发布了新的文献求助20
9秒前
美丽如柏完成签到,获得积分10
9秒前
ZJJ35发布了新的文献求助10
10秒前
11秒前
共享精神的应助被yang采纳,获得10
11秒前
11秒前
11秒前
张伟发布了新的文献求助10
11秒前
zgw发布了新的文献求助10
11秒前
alwayslifted完成签到,获得积分10
11秒前
脑洞疼的应助被Yiphy采纳,获得10
12秒前
小橘子的应助被fanjunkk采纳,获得10
12秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186012
求助须知:如何正确求助?哪些是违规求助? 9574616
关于积分的说明 21837084
捐赠科研通 7783730
什么是DOI,文献DOI怎么找? 3434729
关于科研通互助平台的介绍 2559055
邀请新用户注册赠送积分活动 2481504